In order for pharmaceutical products to be eligible for reimbursement from Medicaid, Texas law requires that manufacturers accurately report market prices to Medicaid. The Medicaid program then uses this drug-pricing information to determine the rates at which pharmacies are reimbursed for products.
The state’s legal action against Actavis stems from a whistleblower lawsuit that was filed under seal by a Florida-based pharmacy, Ven-a-Care. The pharmacy pursued their claim after discovering Actavis reported artificially inflated prices to Medicaid for its drugs. The case against Actavis is the first to go to trial.
Read the news release about Actavis’ verdict.
Read other coverage about pharmaceutical fraud:
– Pharmaceutical Company Will Pay $280M to Settle False Claims Allegations
– Irish Pharmaceutical Company and U.S. Subsidiary to Pay $203M for Off-Label Marketing
– Kos Pharmaceuticals Will Pay $41M to Settle Kickback, Off-Label Promotion Allegations
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
